In this session Wellnex Life MD Zack Bozinovski, CEO George Karafotias and new Board appointment Andrew Vidler discussed how the transformative

In this session Far East Gold’s Chairman Paul Walker and GM of Exploration Mike Corey discussed the high-grade copper and gold mineralization identified through geological mapping and surface rock sampling at the Sentul and Buluroto prospect areas.

In this session Felix Gold Executive Director Joseph Webb discussed Felix’s prospects in the world-class Alaskan region including high grade critical mineral antimony assays of up to 28% Sb.

Join Stuart Roberts, co-founder and senior analyst at Pitt Street Research, for an online briefing where he will outline the recent Pitt Street Research report on Prescient Therapeutics.

In this session Prescient CEO and Managing Director Steven Yatomi-Clarke provide a company update structured in a Q&A format to field key questions from investors. Steven discussed the key highlights.

Felix Gold Limited (ASX: FXG) Managing Director and CEO Anthony Reilly discusses the exploration success the team delivered in the short period since IPO, showing potential to host up to 3.6Moz in NW Array alone and the potential of Felix’ other prospects in this world-class mining region.

EBR Systems Inc (ASX: EBR) is the world’s only provider of wireless, endocardial (inside the heart) pacing systems in a US$2.5 billion addressable market.

Zoom2u Technologies is the parent company of same-day delivery platform Zoom2u and global last mile delivery SaaS platform Locate2u.

Great Boulder is a mineral exploration company with a portfolio of highly prospective gold and base metals assets ranging from greenfields to advanced exploration.

Pureprofile is a data and insights organisation and SaaS operator providing industry-leading online research solutions to agencies, marketers, researchers and brands.

Site Group International (ASX: SIT) International Operations Director Vernon Wills discusses how the company believes they are on the way to achieving circa $31 million revenue in FY25, and how they enable the likes of ExxonMobil, GE and OceanaGold to run successful and safe operations in developing parts of the world.

Prescient Therapeutics (ASX: PTX) CEO and MD Steven Yatomi-Clarke discusses how Prescient is advancing its deep pipeline, including moving OmniCAR towards clinical studies and progressing PTX-100 and PTX-200 further through the clinic. What the recent Q-Gen contract means for producing first OmniCAR T-cells for upcoming clinical trials, based on the encouraging progress of the AML program.